SCHEMBL2498070

SCHEMBL2498070

O=C(c1ccc(F)cc1)c1cn(-c2cccc(-c3cccnc3F)c2)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 10/20 0.35
BACE2 Q9Y5Z0 10/20 0.35
CTSD P07339 9/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DHODH Q02127 2/20 0.35
MLLT3 P42568 1/20 0.35
MLLT1 Q03111 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35
TUBA3E Q6PEY2 1/20 0.35
TUBA1A Q71U36 1/20 0.35
TUBA1C Q9BQE3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2498722 0.91 GRM5 (0.36) BACE1BACE2CTSDKMT2ADHODH
SCHEMBL2497153 0.90 RAB9A (0.40) KMT2AL3MBTL1DHODHMLLT3MLLT1
SCHEMBL2498691 0.89 CTSD (0.46) BACE1BACE2CTSDTUBB4ATUBB
SCHEMBL2501417 0.88 BACE1 (0.37) BACE1BACE2CTSDDHODHMLLT3
SCHEMBL2502844 0.87 HSD17B14 (0.38) BACE1BACE2CTSDKMT2ADHODH
SCHEMBL1887383 0.85 KDM4E (0.41) BACE1BACE2CTSDDHODHMLLT3
SCHEMBL2497610 0.85 SCN9A (0.35) KMT2AL3MBTL1MLLT3MLLT1GRM5
SCHEMBL2500738 0.85 SCN9A (0.43) KMT2ATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2493511 0.84 CYP11B2 (0.38) BACE1BACE2CTSDDHODHMLLT3
SCHEMBL2494379 0.84 ITGB1 (0.41) KMT2AL3MBTL1MLLT3MLLT1TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030339-B2 Imidazole derivatives for the treatment of anxiety and related diseases NEUROSEARCH A/S (DK) 2011-10-04 US claimed
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases NEUROSEARCH A/S (DK) 2009-09-17 US claimed
US-8030339-B2 Imidazole derivatives for the treatment of anxiety and related diseases NEUROSEARCH A/S (DK) 2011-10-04 US disclosed
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases NEUROSEARCH A/S (DK) 2009-09-17 US disclosed
EP-1937649-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2008-07-02 EP disclosed
WO-2007042546-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases GABBR1, GABRB2, GABRB3 BACE1 1809/4885BACE2 1934/4885CTSD 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.